Cellectis Reports Encouraging Clinical Data from BALLI-01
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no...
Source: globenewswire.com
Could Be Specific News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Could Be Specific. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Could Be Specific Today - Breaking & Trending Today
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab with no Dose-Limiting Toxicities in BALLI-01... | December 11, 2021
Source: marketscreener.com